<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCD</journal-id><journal-title-group><journal-title>World Journal of Cardiovascular Diseases</journal-title></journal-title-group><issn pub-type="epub">2164-5329</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/wjcd.2024.143012</article-id><article-id pub-id-type="publisher-id">WJCD-132278</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Two-Stent Strategy for Bifurcation Lesions in Percutaneous Transluminal Coronary Angioplasty: Real-World Evidence
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Dilip</surname><given-names>Kumar</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Amit</surname><given-names>Malviya</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Animesh</surname><given-names>Mishra</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Rabin</surname><given-names>Chakraborty</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sanjeev</surname><given-names>S. Mukherjee</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Soumya</surname><given-names>Patra</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Arindam</surname><given-names>Pande</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Rana</surname><given-names>Rathor Roy</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Debopriyo</surname><given-names>Mondal</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ashesh</surname><given-names>Halder</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sumit</surname><given-names>Shanker</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>North Eastern Indira Gandhi Regional Institute of Health &amp;amp; Medical Sciences (NEIGRIHMS) Mawdiangdiang, 
Shillong, Meghalaya, India</addr-line></aff><aff id="aff1"><addr-line>Medica Superspecialty Hospital 127, Eastern Metropolitan Bypass, Nitai Nagar, Mukundapur, Kolkata, 
West Bengal, India</addr-line></aff><pub-date pub-type="epub"><day>26</day><month>03</month><year>2024</year></pub-date><volume>14</volume><issue>03</issue><fpage>140</fpage><lpage>156</lpage><history><date date-type="received"><day>1,</day>	<month>December</month>	<year>2023</year></date><date date-type="rev-recd"><day>26,</day>	<month>March</month>	<year>2024</year>	</date><date date-type="accepted"><day>29,</day>	<month>March</month>	<year>2024</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background:
   Bifurcation lesions pose a high risk for adverse events after percutaneous coronary intervention (PCI). Evidence supporting the benefits of the two-stent strategy (2SS) for treating coronary bifurcation lesions in India is limited. This study aimed to evaluate the clinical outcomes of various 2SSs for percutaneous transluminal coronary angioplasty for bifurcation lesions in India. <b>Materials and Methods:</b> This retrospective, observational, multicentric, real-world study included 64 patients over 8 years. Data on demographics, medical history, PCI procedures, and outcomes were recorded. Descriptive statistics were computed using the SPSS software. <b>Results:</b> Patients (n
   
  =
   
  64) had an average age of 65.3
   
  &#177;
   
  11.1 years, with 78.1% males. Acute coronary syndrome was reported in 18.8%, chronic stable angina in 40.6%, and unstable angina in 34.4% of participants. Two-vessel disease was observed in 98.4% of patients, and 99.4% had true bifurcation lesions. The commonly involved vessels were the left anterior descending artery (50%), left circumflex coronary artery (34.4%), and first diagonal artery (43.8%). Mean percent diameter stenosis was 87.2
  % 
  &#177;
   
  10.1%. The mean number of stents used was 2.00
   
  &#177;
   
  0.34. The 2SS techniques included the T and small protrusion (TAP) (39.1%), double kissing (DK) crush (18.8%), and the culotte techniques (14.1%). Procedural and angiographic success rate was 92.18%. Major adverse cardiovascular events at 1-year follow-up occurred in 7.8% of cases. <b>Conclusion:</b> The 2SS for bifurcation lesions showed favorable in-hospital and follow-up outcomes. Findings can serve as a resource for bifurcation angioplasty in India. Larger real-world studies with robust methodology are needed to validate these results.
 
</p></abstract><kwd-group><kwd>Bifurcation Stenting</kwd><kwd> Coronary Bifurcation Lesions</kwd><kwd> Percutaneous</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Percutaneous coronary intervention (PCI) or percutaneous transluminal coronary angioplasty (PTCA) is the preferred approach for treating bifurcation lesions [<xref ref-type="bibr" rid="scirp.132278-ref1">1</xref>] . Coronary bifurcation lesions (CBLs) occur in 15% - 20% of all PCIs and are associated with greater probabilities of unfavorable outcomes as compared to non-bifurcation lesions [<xref ref-type="bibr" rid="scirp.132278-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.132278-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.132278-ref4">4</xref>] . According to data from the National Interventional Council (India, 2018), 4.32% of all PCIs in India required bifurcation coronary stenting [<xref ref-type="bibr" rid="scirp.132278-ref5">5</xref>] .</p><p>Bifurcation lesions are susceptible to atherosclerosis because of their distinctive local blood flow patterns and endothelial shear stress in the areas where they occur. Although the relatively high blood flow rates in these areas prevent atheroma development in the carina, plaques develop opposite to the carina owing to reduced endothelial shear stress [<xref ref-type="bibr" rid="scirp.132278-ref6">6</xref>] . As these lesions may have highly variable anatomies, structures, pathological conditions, and severities, no single strategy is applicable to their treatment [<xref ref-type="bibr" rid="scirp.132278-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.132278-ref7">7</xref>] .</p><p>Drug-eluting stent (DES) devices have progressively replaced balloon angioplasty and bare metal stents (BMSs). Compared with BMSs, first-generation DESs significantly decreased the likelihood of restenosis, although this benefit was negated by their association with late stent thrombosis. However, with second-generation DESs, the occurrence of 1-year stent thrombosis is &lt;1%. The DESs currently used are sirolimus, everolimus, and zotarolimus [<xref ref-type="bibr" rid="scirp.132278-ref8">8</xref>] .</p><p>The decision to use provisional stenting (PS) or a two-stent strategy (2SS) in different anatomic scenarios has been a challenge for many interventionalists [<xref ref-type="bibr" rid="scirp.132278-ref5">5</xref>] . The 2019 European Bifurcation Club (EBC) recommends the PS strategy technique as the preferred technique for treating CBLs and restricts the use of upfront 2SS in selected cases with adequate preparation of the lesion, proximal optimization technique (POT), and final kissing balloon inflation (FKBI) [<xref ref-type="bibr" rid="scirp.132278-ref3">3</xref>] (Park 2022). The presence of a large side branch (SB) in a bifurcation lesion also warrants treatment of the SB [<xref ref-type="bibr" rid="scirp.132278-ref4">4</xref>] .</p><p>Although PS is the preferred strategy for treating CBLs, it is associated with complications such as ostial occlusion of the SB, stent deformation, malpositioning, fracture, plaque shift, and changes in bifurcation angle [<xref ref-type="bibr" rid="scirp.132278-ref9">9</xref>] . However, 2SS involves the overlapping of multiple layers of the stent, resulting in the formation of a neocarina, which may cause major adverse cardiac events (MACEs) [<xref ref-type="bibr" rid="scirp.132278-ref10">10</xref>] .</p><p>The appropriate technique for upfront double stenting is selected based on the anatomy and complexity of the lesion [<xref ref-type="bibr" rid="scirp.132278-ref7">7</xref>] . However, there is no agreement on a standard management technique for CBLs in which the application of second generation DESs does not improve outcomes after PCI [<xref ref-type="bibr" rid="scirp.132278-ref11">11</xref>] .</p><p>Although several bifurcation coronary stenting (BCS) strategies are used in PCIs, it is unclear which is ideal for achieving optimal results when treating CBLs [<xref ref-type="bibr" rid="scirp.132278-ref5">5</xref>] . In addition, there is limited systematic data on the use of different BCS strategies and their outcomes in Indian settings. This real-world study assessed the clinical outcomes of using various 2SSs for the PTCA of bifurcation lesions in India.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Ethical Consideration</title><p>This retrospective, observational, multicenter, real-world study included all coronary bifurcation cases requiring PCI during 2014-2022. Ethical approval and written informed consent were obtained from all the patients. This study was conducted in compliance with the principles of the Declaration of Helsinki.</p></sec><sec id="s2_2"><title>2.2. Study Population</title><p>A total of sixty-four patients were enrolled in the study using convenience sampling. The sample size for the study was estimated using G* Power 3.1.9.2 software keeping power of the study as 80%, alpha error as 0.5, and the effect size as 0.2. The study employed a targeted approach to participant selection, focusing on patients with specific clinical indications for bifurcation PCI using a two-stent strategy, and used convenience sampling to recruit participants based on their availability and willingness to participate. The study included patients who had a history of acute coronary syndrome (ACS), chronic stable angina (CSA), or myocardial infarction (MI) and were undergoing coronary stenting for bifurcation lesions. The key inclusion criteria were patients requiring bifurcation percutaneous coronary intervention (PCI) with a two-stent strategy (2SS). The exclusion criteria were patients who were in cardiogenic shock at the time of the procedure and those undergoing routine hemodialysis before the procedure.</p></sec><sec id="s2_3"><title>2.3. Study Data Collection</title><p>Data on demographics and comorbidities (diabetes mellitus [DM], hypertension, smoking, and antiplatelet therapy) of the patients were collected. Coronary angiogram was performed to detect any obstructions in the coronary arteries. The CBLs were categorized according to the Medina classification system. The characteristics of the lesions that were noted included the type of the lesion, length of the lesion, severity of coronary stenosis, local presence of thrombus, and the presence/extent of calcification. The data regarding all the variables were retrospectively reviewed in detail and collected from the hospital records where these patients were operated on. If necessary, further data on the patients were collected via telephonic conversations with the hospital personnel and the patients themselves.</p><p>The procedural characteristics included access location, size of guiding catheters, type of stent used, number of stents placed per patient, stent diameter and length, type of DES used, and grade of thrombolysis in myocardial infarction (TIMI) flow grade. The use of POT, FKBI, and intravascular ultrasound (IVUS) was also recorded. The details of the stents used are provided in Supplementary <xref ref-type="table" rid="table">Table </xref>S1.</p></sec><sec id="s2_4"><title>2.4. PCI Procedure</title><p>Before enrolment in the study, the patients were on antiplatelets (64%), statins (43.8%), nitrates (21.9%), antidiabetic drugs (34.4%), beta-blockers (4.7%), and ivabradine (3.1%). The procedures were performed according to the standard protocols. Factors such as access location, use of diagnostic and guiding catheters, choice of treatment strategy, stenting method, generation of DES, POT, FKBI, and IVUS were included in the judgment of the investigators involved in the study. Achieving TIMI grade 3 flow in treated vessels served as a measure of angiographic success. A successful angiographic result without the incidence of any serious complication (death, MI, or coronary artery bypass graft) before discharge was considered a procedural success. Stent thrombosis was the safety endpoint. Drugs such as statins (100%), ticagrelor (100%), nitrates (100%), aspirin (100%), angiotensin-converting enzyme inhibitors (73.4%), beta-blockers (96.9%), antidiabetic drugs (34.4%), angiotensin receptor neprilysin inhibitors (15.6%), ivabradine (6.3%), and angiotensin receptor blockers (25%) were prescribed to the patients after PCI.</p></sec><sec id="s2_5"><title>2.5. Follow-Up</title><p>A 12-month clinical follow-up was achieved for all patients (via visits to the clinic or telephonic conversations). Follow-up MACEs were defined as the occurrence of cardiac death, nonfatal MI, or target lesion revascularization.</p></sec><sec id="s2_6"><title>2.6. Statistical Analysis</title><p>The statistical analysis was performed using SPSS (version 20.0; IBM, SPSS Inc., Chicago, IL, USA). Categorical variables are presented as frequencies and percentages (%) and continuous variables were presented as mean &#177; SD and median.</p></sec></sec><sec id="s3"><title>3. Results</title><p><xref ref-type="table" rid="table">Table </xref>1 outlines the patient-related characteristics. Most patients were men (78.1%); the mean age was 65.3 &#177; 11.1 years; and the mean body mass index was 25.59 &#177; 3.95 kg/m<sup>2</sup>. Comorbidities such as DM, hypertension, and smoking were present in 32.8%, 64.1%, and 18.8% of the patients, respectively. ACS was reported in 18.8%, CSA in 40.6%, and unstable angina (UA) in 34.4% of the</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table">Table </xref>1</label><caption><title> Baseline clinical characteristics of patients included in this study (N = 64)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variables</th><th align="center" valign="middle" >Values</th></tr></thead><tr><td align="center" valign="middle" >Age (years)(mean &#177; SD; range)</td><td align="center" valign="middle" >65.3 &#177; 11.1; 40 - 91</td></tr><tr><td align="center" valign="middle" >Gender (male/female) N (%)</td><td align="center" valign="middle" >50/14 (78.1/21.9)</td></tr><tr><td align="center" valign="middle" >BMI (mean &#177; SD; range)</td><td align="center" valign="middle" >25.59 &#177; 3.95; 19.92 - 31.63</td></tr><tr><td align="center" valign="middle" >Medical history and risk factors</td><td align="center" valign="middle" >N (%)</td></tr><tr><td align="center" valign="middle" >Hypertension</td><td align="center" valign="middle" >41 (64.1)</td></tr><tr><td align="center" valign="middle" >Diabetes mellitus</td><td align="center" valign="middle" >21 (32.8)</td></tr><tr><td align="center" valign="middle" >Smoking habits</td><td align="center" valign="middle" >12 (18.8)</td></tr><tr><td align="center" valign="middle" >Antiplatelet therapy</td><td align="center" valign="middle" >64 (100)</td></tr><tr><td align="center" valign="middle" >Diagnosis</td><td align="center" valign="middle" >N (%)</td></tr><tr><td align="center" valign="middle" >CSA</td><td align="center" valign="middle" >26 (40.6)</td></tr><tr><td align="center" valign="middle" >UA</td><td align="center" valign="middle" >22 (34.4)</td></tr><tr><td align="center" valign="middle" >ACS</td><td align="center" valign="middle" >12 (18.8)</td></tr><tr><td align="center" valign="middle" >NSTEMI</td><td align="center" valign="middle" >1 (1.6)</td></tr><tr><td align="center" valign="middle" >AWMI</td><td align="center" valign="middle" >2 (3.1)</td></tr><tr><td align="center" valign="middle" >IWMI</td><td align="center" valign="middle" >1 (1.6)</td></tr></tbody></table></table-wrap><p>ACS: Acute coronary syndrome; AWMI: Anterior wall myocardial infarction; BMI: Body mass index; CSA: Chronic stable angina; IWMI: Inferior wall myocardial infarction; NSTEMI: Non-ST-elevation myocardial infarction; SD: Standard deviation; UA: Unstable angina.</p><p>participants. All the patients were on antiplatelet therapy.</p><p>The two-vessel disease was observed in 98.4% of the patients. The vessels commonly involved in bifurcation lesions were the left anterior descending (LAD; 50%), left circumflex coronary artery (LCX; 34.4%), left main coronary artery-left anterior descending (LMCA-LAD; 3.1%), and first diagonal artery (D1; 43.8%). Both true and nontrue Medina CBLs were included in the study. True CBLs were found in 98.4% of the patients. Most of the patients (68.8%) had type B lesions. Thrombus and calcified lesions were seen in 10.9% and 25% of the patients, respectively. In 43.7% of the patients, the main branch (MB) lesion was more than 20 mm in length. The mean percent diameter stenosis was 87.2% &#177; 10.1% (<xref ref-type="table" rid="table">Table </xref>2).</p><p>The procedural details of the PCIs are shown in <xref ref-type="table" rid="table">Table </xref>3. The femoral route was used in 57.8% of the patients and a guide catheter of size 6 was used in 64.1% of the patients. Two stents were implanted in 98.4% of the patients. The mean number of stents used in the study was 2.09 &#177; 0.34. Some of the 2SSs used were the TAP technique (39.1%), the DK crush (18.8%), and the culotte technique (14.1%). Sirolimus-, everolimus-, and zotarolimus-containing DESs were used in 52.3%, 34.4%, and 13.3% of the patients, respectively. The FKBI and POT sequences were performed in 85.9% and 79.7% of the patients, respectively, and TIMI grade 3 flow was achieved in 100% of the patients.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table">Table </xref>2</label><caption><title> Lesion characteristics (N = 64)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variables</th><th align="center" valign="middle" >Values N (%)</th></tr></thead><tr><td align="center" valign="middle" >Extent of CAD</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Two vessels</td><td align="center" valign="middle" >63 (98.4)</td></tr><tr><td align="center" valign="middle" >Three vessels</td><td align="center" valign="middle" >1 (1.6)</td></tr><tr><td align="center" valign="middle" >Bifurcation lesion location</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >LAD</td><td align="center" valign="middle" >32 (50)</td></tr><tr><td align="center" valign="middle" >LCX</td><td align="center" valign="middle" >22 (34.4)</td></tr><tr><td align="center" valign="middle" >LMCA-LAD</td><td align="center" valign="middle" >2 (3.1)</td></tr><tr><td align="center" valign="middle" >LMCA-LCX</td><td align="center" valign="middle" >5 (7.8)</td></tr><tr><td align="center" valign="middle" >LPDA</td><td align="center" valign="middle" >1 (1.6)</td></tr><tr><td align="center" valign="middle" >PDA</td><td align="center" valign="middle" >1 (1.6)</td></tr><tr><td align="center" valign="middle" >RCA-PDA</td><td align="center" valign="middle" >2 (3.1)</td></tr><tr><td align="center" valign="middle" >SVG-PDA</td><td align="center" valign="middle" >1 (1.6)</td></tr><tr><td align="center" valign="middle" >PLV</td><td align="center" valign="middle" >4 (6.3)</td></tr><tr><td align="center" valign="middle" >D1</td><td align="center" valign="middle" >28 (43.8)</td></tr><tr><td align="center" valign="middle" >D2</td><td align="center" valign="middle" >3 (4.7)</td></tr><tr><td align="center" valign="middle" >OM1</td><td align="center" valign="middle" >6 (9.4)</td></tr><tr><td align="center" valign="middle" >OM2</td><td align="center" valign="middle" >6 (9.4)</td></tr><tr><td align="center" valign="middle" >OM1 and OM2</td><td align="center" valign="middle" >1 (1.6)</td></tr><tr><td align="center" valign="middle" >Lesion type</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Type B</td><td align="center" valign="middle" >44 (68.8)</td></tr><tr><td align="center" valign="middle" >Type C</td><td align="center" valign="middle" >20 (31.3)</td></tr><tr><td align="center" valign="middle" >Medina classification</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >1, 1, 1</td><td align="center" valign="middle" >40 (62.5)</td></tr><tr><td align="center" valign="middle" >0, 1, 1</td><td align="center" valign="middle" >20 (31.3)</td></tr><tr><td align="center" valign="middle" >1, 0, 1</td><td align="center" valign="middle" >3 (4.7)</td></tr><tr><td align="center" valign="middle" >1, 1, 0</td><td align="center" valign="middle" >1 (1.6)</td></tr><tr><td align="center" valign="middle" >Main branch lesion length</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;20 mm lesion</td><td align="center" valign="middle" >36 (56.3)</td></tr><tr><td align="center" valign="middle" >&gt;20 mm lesion</td><td align="center" valign="middle" >28 (43.7)</td></tr><tr><td align="center" valign="middle" >Thrombus</td><td align="center" valign="middle" >7 (10.9)</td></tr><tr><td align="center" valign="middle" >Calcium</td><td align="center" valign="middle" >16 (25)</td></tr><tr><td align="center" valign="middle" >Main branch percent diameter stenosis (mean &#177; SD)</td><td align="center" valign="middle" >87.2% &#177; 10.1%</td></tr></tbody></table></table-wrap><p>CAD: Coronary artery disease; D1: First diagonal artery; D2: Second diagonal artery; LAD: Left anterior descending; LCX: Left circumflex coronary artery; LMCA-LAD: Left main coronary artery-left anterior descending; LMCA-LCX: Left main coronary artery-left circumflex coronary artery; LPDA: Left posterior descending artery; OM: Obtuse marginal artery; OM1: First obtuse marginal artery; OM2: Second obtuse marginal artery; PDA: Posterior descending artery; PLV: Posterior left ventricular; RCA-PDA: Right coronary artery-posterior descending artery; SD: Standard deviation; SVG-PDA: Saphenous vein graft-posterior descending artery.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table">Table </xref>3</label><caption><title> Procedural characteristics (N = 64)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variables</th><th align="center" valign="middle" >Values</th></tr></thead><tr><td align="center" valign="middle" >Two-stent techniques</td><td align="center" valign="middle" >N (%)</td></tr><tr><td align="center" valign="middle" >Culotte technique</td><td align="center" valign="middle" >9 (14.1)</td></tr><tr><td align="center" valign="middle" >DK crush</td><td align="center" valign="middle" >12 (18.8)</td></tr><tr><td align="center" valign="middle" >Kissing</td><td align="center" valign="middle" >2 (3.1)</td></tr><tr><td align="center" valign="middle" >Mini-crush</td><td align="center" valign="middle" >6 (9.4)</td></tr><tr><td align="center" valign="middle" >Nano-crush</td><td align="center" valign="middle" >1 (1.6)</td></tr><tr><td align="center" valign="middle" >Reverse mini-crush technique</td><td align="center" valign="middle" >1 (1.6)</td></tr><tr><td align="center" valign="middle" >SKS</td><td align="center" valign="middle" >2 (3.1)</td></tr><tr><td align="center" valign="middle" >Stent plus DEB</td><td align="center" valign="middle" >1 (1.6)</td></tr><tr><td align="center" valign="middle" >T stenting</td><td align="center" valign="middle" >5 (7.8)</td></tr><tr><td align="center" valign="middle" >TAP technique</td><td align="center" valign="middle" >25 (39.1)</td></tr><tr><td align="center" valign="middle" >Stents placed per patient</td><td align="center" valign="middle" >N (%)</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >63 (98.4)</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1 (1.6)</td></tr><tr><td align="center" valign="middle" >Mean &#177; SD</td><td align="center" valign="middle" >2.09 &#177; 0.34</td></tr><tr><td align="center" valign="middle" >Stenting technique</td><td align="center" valign="middle" >N (%)</td></tr><tr><td align="center" valign="middle" >Sirolimus-eluting stent</td><td align="center" valign="middle" >67 (52.3)</td></tr><tr><td align="center" valign="middle" >Everolimus-eluting stent</td><td align="center" valign="middle" >44 (34.4)</td></tr><tr><td align="center" valign="middle" >Zotarolimus-eluting stent</td><td align="center" valign="middle" >17 (13.3)</td></tr><tr><td align="center" valign="middle" >Access site</td><td align="center" valign="middle" >N (%)</td></tr><tr><td align="center" valign="middle" >Femoral</td><td align="center" valign="middle" >37 (57.8)</td></tr><tr><td align="center" valign="middle" >Radial</td><td align="center" valign="middle" >27 (42.2)</td></tr><tr><td align="center" valign="middle" >Guide catheter</td><td align="center" valign="middle" >N (%)</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >41 (64.1)</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >23 (35.9)</td></tr><tr><td align="center" valign="middle" >Final kissing balloon inflation</td><td align="center" valign="middle" >55 (85.9)</td></tr><tr><td align="center" valign="middle" >Proximal optimization technique</td><td align="center" valign="middle" >51 (79.7)</td></tr><tr><td align="center" valign="middle" >Intravascular ultrasonography</td><td align="center" valign="middle" >6 (9.4)</td></tr><tr><td align="center" valign="middle" >TIMI grade 3 flow</td><td align="center" valign="middle" >64 (100)</td></tr></tbody></table></table-wrap><p>DEB: Drug-eluting balloon; DK: Double kissing; MB: Main branch; SB: Side branch; SD: Standard deviation; SKS: Simultane ous kissing stent; TAP: T and protrusion; TIMI: Thrombolysis in myocardial infarction.</p><p>The outcomes of the PCI procedures are shown in <xref ref-type="table" rid="table">Table </xref>4. At follow-up, MACE was reported in five patients (7.8%). Of these, one patient (1.6%) experienced cardiogenic shock, another patient (1.6%) experienced chest pain/angina, and three of the patients (4.7%) died due to stent thrombosis. The procedural and angiographic success rate considering the MACE events was 92.18%.</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table">Table </xref>4</label><caption><title> Outcome characteristics (in-hospital and follow-up) (N = 64)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variables</th><th align="center" valign="middle" >N (%)</th></tr></thead><tr><td align="center" valign="middle" >Cardiogenic shock</td><td align="center" valign="middle" >1 (1.6)</td></tr><tr><td align="center" valign="middle" >Chest pain, angina</td><td align="center" valign="middle" >1 (1.6)</td></tr><tr><td align="center" valign="middle" >Expired due to stent thrombosis</td><td align="center" valign="middle" >3 (4.7)</td></tr></tbody></table></table-wrap></sec><sec id="s4"><title>4. Discussion</title><p>This study indicates that the application of the 2SS in the Indian context has favorable in-hospital and follow-up outcomes. This is one among the initial studies in the Indian population, which examines the outcomes of using a 2SS for treating complex lesions in a sample of 64 patients. Coronary bifurcation lesions can vary significantly in the angles of the bifurcations as well as in the sizes of the side branch and main vessel [<xref ref-type="bibr" rid="scirp.132278-ref12">12</xref>] . Although two large randomized controlled trials, the Nordic bifurcation study (NORDIC I) and the British Bifurcation Coronary Study (BBC ONE), support PS over 2SS (as the latter approach resulted in higher rates of in-hospital adverse cardiovascular events), it should be noted that these studies did not differentiate between true and non-true bifurcations. In addition, FKBI and POT were not employed in all the patients, thereby contributing to the reported results [<xref ref-type="bibr" rid="scirp.132278-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.132278-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.132278-ref15">15</xref>] . The EBC recommends the use of stepwise layered PS strategy in cases with CBL, wherein a single stent is planned and when a 2SS is anticipated pre-procedurally [<xref ref-type="bibr" rid="scirp.132278-ref16">16</xref>] .</p><p>Nevertheless, there are also several reports favoring 2SS over PS in CBL. According to the multicenter randomized DEFINITION II trial, which compared the use of 2SS with that of PS among 653 patients with CBL, the 2SS approach demonstrated a significant enhancement in the clinical outcomes with respect to target lesion failure, target vessel myocardial infarction, and clinically-driven target lesion revascularization when compared to the PS approach [<xref ref-type="bibr" rid="scirp.132278-ref12">12</xref>] . The European Bifurcation Coronary TWO (EBC TWO) study comparing the use of PS and 2SS among 200 patients with large caliber true bifurcation lesions demonstrated that both techniques were comparable with respect to death, myocardial infarction, and target vessel revascularization at a follow-up of 12 months [<xref ref-type="bibr" rid="scirp.132278-ref17">17</xref>] .</p><p>Similar results were reported by the Nordic-Baltic Bifurcation Study-IV, a randomized multicentric study wherein MACE at 2 years was 12.9% in the PS group and 8.4% in the 2SS group; the differences in MACE between these two groups were not statistically significant [<xref ref-type="bibr" rid="scirp.132278-ref18">18</xref>] . Studies in the literature have used different techniques of double-stenting strategy, few have included only left main bifurcations and others excluded left main bifurcations. In addition, many of these studies vary in the sizes of the MB and SB values. <xref ref-type="table" rid="table">Table </xref>5 shows a compilation of studies that investigated the use of a 2SS in treating CBLs between 2004 and 2021 [<xref ref-type="bibr" rid="scirp.132278-ref19">19</xref>] - [<xref ref-type="bibr" rid="scirp.132278-ref38">38</xref>] .</p><p>The preponderance of males undergoing PCIs in this study is a commonly occurring pattern and is supported by various meta-analyses [<xref ref-type="bibr" rid="scirp.132278-ref39">39</xref>] [<xref ref-type="bibr" rid="scirp.132278-ref40">40</xref>] [<xref ref-type="bibr" rid="scirp.132278-ref41">41</xref>] [<xref ref-type="bibr" rid="scirp.132278-ref42">42</xref>]</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table">Table </xref>5</label><caption><title> Summary of studies with a two-stent strategy for the treatment of coronary bifurcation lesion</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Study</th><th align="center" valign="middle" >Interventions</th><th align="center" valign="middle" >Sample size</th><th align="center" valign="middle" >Age (years) mean &#177; SD</th><th align="center" valign="middle" >Male n (%)</th><th align="center" valign="middle" >Final KB n (%)</th><th align="center" valign="middle" >Procedural success n (%)</th></tr></thead><tr><td align="center" valign="middle" >Pan et al. 2004 [<xref ref-type="bibr" rid="scirp.132278-ref19">19</xref>]</td><td align="center" valign="middle" >T/TAP</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >58 &#177; 11</td><td align="center" valign="middle" >38 (86)</td><td align="center" valign="middle" >34 (77)</td><td align="center" valign="middle" >43 (97)</td></tr><tr><td align="center" valign="middle" >Colombo et al. 2004 [<xref ref-type="bibr" rid="scirp.132278-ref20">20</xref>]</td><td align="center" valign="middle" >T/TAP</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >63 &#177; 10</td><td align="center" valign="middle" >48 (76)</td><td align="center" valign="middle" >57 (90)</td><td align="center" valign="middle" >58 (92)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >DK-Crush I 2008 [<xref ref-type="bibr" rid="scirp.132278-ref21">21</xref>]</td><td align="center" valign="middle" >Crush</td><td align="center" valign="middle" >156</td><td align="center" valign="middle" >64 &#177; 9</td><td align="center" valign="middle" >109 (70)</td><td align="center" valign="middle" >124 (76)</td><td align="center" valign="middle" >142 (91.1)</td></tr><tr><td align="center" valign="middle" >DK crush</td><td align="center" valign="middle" >155</td><td align="center" valign="middle" >64 &#177; 9</td><td align="center" valign="middle" >118 (76)</td><td align="center" valign="middle" >161 (100)</td><td align="center" valign="middle" >149 (96.1)</td></tr><tr><td align="center" valign="middle" >CACTUS 2009 [<xref ref-type="bibr" rid="scirp.132278-ref22">22</xref>]</td><td align="center" valign="middle" >Crush</td><td align="center" valign="middle" >177</td><td align="center" valign="middle" >65 &#177; 10</td><td align="center" valign="middle" >142 (80)</td><td align="center" valign="middle" >163 (92)</td><td align="center" valign="middle" >160 (90)</td></tr><tr><td align="center" valign="middle" >Hildick-Smith et al. 2010 [<xref ref-type="bibr" rid="scirp.132278-ref14">14</xref>]</td><td align="center" valign="middle" >2-stent</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >64 &#177; 11</td><td align="center" valign="middle" >193 (77)</td><td align="center" valign="middle" >189 (76)</td><td align="center" valign="middle" >234 (94)</td></tr><tr><td align="center" valign="middle" >DK-Crush II 2011 [<xref ref-type="bibr" rid="scirp.132278-ref23">23</xref>]</td><td align="center" valign="middle" >DK</td><td align="center" valign="middle" >185</td><td align="center" valign="middle" >64 &#177; 11</td><td align="center" valign="middle" >146 (79)</td><td align="center" valign="middle" >183 (100)</td><td align="center" valign="middle" >179 (96.8)</td></tr><tr><td align="center" valign="middle" >Ye et al. 2012 [<xref ref-type="bibr" rid="scirp.132278-ref24">24</xref>]</td><td align="center" valign="middle" >DK crush</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >63 &#177; 10</td><td align="center" valign="middle" >24 (63)</td><td align="center" valign="middle" >38 (100)</td><td align="center" valign="middle" >38 (100)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >NSTS 2013 [<xref ref-type="bibr" rid="scirp.132278-ref25">25</xref>]</td><td align="center" valign="middle" >Crush</td><td align="center" valign="middle" >209</td><td align="center" valign="middle" >65 &#177; 10</td><td align="center" valign="middle" >149 (71)</td><td align="center" valign="middle" >177 (85)</td><td align="center" valign="middle" >205 (98)</td></tr><tr><td align="center" valign="middle" >Culotte</td><td align="center" valign="middle" >215</td><td align="center" valign="middle" >65 &#177; 11</td><td align="center" valign="middle" >154 (71)</td><td align="center" valign="middle" >197 (92)</td><td align="center" valign="middle" >210 (98)</td></tr><tr><td align="center" valign="middle" >NBS 2013 [<xref ref-type="bibr" rid="scirp.132278-ref26">26</xref>]</td><td align="center" valign="middle" >2-stent</td><td align="center" valign="middle" >202</td><td align="center" valign="middle" >63 &#177; 10</td><td align="center" valign="middle" >162 (79)</td><td align="center" valign="middle" >152 (74)</td><td align="center" valign="middle" >194 (97)</td></tr><tr><td align="center" valign="middle" >Ruiz-Salmer&#243;n et al. 2013 [<xref ref-type="bibr" rid="scirp.132278-ref27">27</xref>]</td><td align="center" valign="middle" >T-stenting</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >64 &#177; 13</td><td align="center" valign="middle" >28 (78)</td><td align="center" valign="middle" >23 (64)</td><td align="center" valign="middle" >34 (94)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >DK-Crush III 2015 [<xref ref-type="bibr" rid="scirp.132278-ref28">28</xref>]</td><td align="center" valign="middle" >DK crush</td><td align="center" valign="middle" >210</td><td align="center" valign="middle" >64 &#177; 10</td><td align="center" valign="middle" >162 (77)</td><td align="center" valign="middle" >209 (99)</td><td align="center" valign="middle" >203 (97)</td></tr><tr><td align="center" valign="middle" >Culotte</td><td align="center" valign="middle" >209</td><td align="center" valign="middle" >63 &#177; 9</td><td align="center" valign="middle" >167 (80)</td><td align="center" valign="middle" >208 (99)</td><td align="center" valign="middle" >201 (96)</td></tr><tr><td align="center" valign="middle" >BBK I 2015 [<xref ref-type="bibr" rid="scirp.132278-ref29">29</xref>]</td><td align="center" valign="middle" >T-stenting</td><td align="center" valign="middle" >101</td><td align="center" valign="middle" >67 &#177; 10</td><td align="center" valign="middle" >79 (78)</td><td align="center" valign="middle" >101 (100)</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >PERFECT 2015 [<xref ref-type="bibr" rid="scirp.132278-ref30">30</xref>]</td><td align="center" valign="middle" >Crush</td><td align="center" valign="middle" >213</td><td align="center" valign="middle" >61 &#177; 9</td><td align="center" valign="middle" >160 (75)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Zhang et al. 2016 [<xref ref-type="bibr" rid="scirp.132278-ref31">31</xref>]</td><td align="center" valign="middle" >Culotte</td><td align="center" valign="middle" >52</td><td align="center" valign="middle" >64 &#177; 7</td><td align="center" valign="middle" >43 (83)</td><td align="center" valign="middle" >48 (92)</td><td align="center" valign="middle" >51 (98)</td></tr><tr><td align="center" valign="middle" >Hildick-Smith et al. 2016 [<xref ref-type="bibr" rid="scirp.132278-ref17">17</xref>]</td><td align="center" valign="middle" >Culotte</td><td align="center" valign="middle" >97</td><td align="center" valign="middle" >63 &#177; 12</td><td align="center" valign="middle" >76 (78)</td><td align="center" valign="middle" >93 (96)</td><td align="center" valign="middle" >95 (98)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >BBK II 2016 [<xref ref-type="bibr" rid="scirp.132278-ref32">32</xref>]</td><td align="center" valign="middle" >Culotte</td><td align="center" valign="middle" >150</td><td align="center" valign="middle" >66 &#177; 11</td><td align="center" valign="middle" >107 (71)</td><td align="center" valign="middle" >150 100)</td><td align="center" valign="middle" >150 (100)</td></tr><tr><td align="center" valign="middle" >TAP</td><td align="center" valign="middle" >150</td><td align="center" valign="middle" >69 &#177; 10</td><td align="center" valign="middle" >114 (76)</td><td align="center" valign="middle" >150 100)</td><td align="center" valign="middle" >148 (99)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Zheng et al. 2016 [<xref ref-type="bibr" rid="scirp.132278-ref33">33</xref>]</td><td align="center" valign="middle" >Crush</td><td align="center" valign="middle" >150</td><td align="center" valign="middle" >63 &#177; 8</td><td align="center" valign="middle" >109 (73)</td><td align="center" valign="middle" >145 (97)</td><td align="center" valign="middle" >145 (97)</td></tr><tr><td align="center" valign="middle" >Culotte</td><td align="center" valign="middle" >150</td><td align="center" valign="middle" >64 &#177; 9</td><td align="center" valign="middle" >111 (74)</td><td align="center" valign="middle" >148 (99)</td><td align="center" valign="middle" >148 (99)</td></tr><tr><td align="center" valign="middle" >DK-Crush IV 2017 [<xref ref-type="bibr" rid="scirp.132278-ref34">34</xref>]</td><td align="center" valign="middle" >DK crush</td><td align="center" valign="middle" >183</td><td align="center" valign="middle" >64 &#177; 11</td><td align="center" valign="middle" >145 (79)</td><td align="center" valign="middle" >183 (100)</td><td align="center" valign="middle" >183 (100)</td></tr><tr><td align="center" valign="middle" >DK-Crush V 2019 [<xref ref-type="bibr" rid="scirp.132278-ref35">35</xref>]</td><td align="center" valign="middle" >DK crush</td><td align="center" valign="middle" >240</td><td align="center" valign="middle" >65 &#177; 9</td><td align="center" valign="middle" >199 83)</td><td align="center" valign="middle" >236 (98)</td><td align="center" valign="middle" >236 (98)</td></tr><tr><td align="center" valign="middle" >NBBS IV 2020 [<xref ref-type="bibr" rid="scirp.132278-ref18">18</xref>]</td><td align="center" valign="middle" >2-stent</td><td align="center" valign="middle" >228</td><td align="center" valign="middle" >63 &#177; 11</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >208 (91.2)</td><td align="center" valign="middle" >226 (98.7)</td></tr><tr><td align="center" valign="middle" >DEFINITION II 2020 [<xref ref-type="bibr" rid="scirp.132278-ref36">36</xref>]</td><td align="center" valign="middle" >2-stent</td><td align="center" valign="middle" >328</td><td align="center" valign="middle" >63 &#177; 11</td><td align="center" valign="middle" >255 (78)</td><td align="center" valign="middle" >323 (99)</td><td align="center" valign="middle" >323 (99)</td></tr><tr><td align="center" valign="middle" >SMART STRATEGY 2020 [<xref ref-type="bibr" rid="scirp.132278-ref37">37</xref>]</td><td align="center" valign="middle" >2-stent</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >66 &#177; 11</td><td align="center" valign="middle" >16 (70)</td><td align="center" valign="middle" >22 (96)</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >EBC Main 2021 [<xref ref-type="bibr" rid="scirp.132278-ref38">38</xref>]</td><td align="center" valign="middle" >2-stent</td><td align="center" valign="middle" >237</td><td align="center" valign="middle" >71 &#177; 10</td><td align="center" valign="middle" >177 (74)</td><td align="center" valign="middle" >219 (92)</td><td align="center" valign="middle" >219 (92)</td></tr><tr><td align="center" valign="middle" >Current study</td><td align="center" valign="middle" >2-stent</td><td align="center" valign="middle" >64</td><td align="center" valign="middle" >65.3 &#177; 11.1</td><td align="center" valign="middle" >50 (78.1)</td><td align="center" valign="middle" >55 (85.9)</td><td align="center" valign="middle" >63 (98.4)</td></tr></tbody></table></table-wrap><p>BBK: Bifurcations Bad Krozingen; CACTUS: Coronary bifurcations: Application of the crushing technique using sirolimus-eluting stents; DK: Double kissing; EBC: European bifurcation coronary; KB: Kissing balloon; NBBS: Nordic-Baltic bifurcation study; NBS: Nordic bifurcation study; NSTS: Nordic stent technique study; SMART: Smart angioplasty research team.</p><p>[<xref ref-type="bibr" rid="scirp.132278-ref43">43</xref>] . The mean age of patients (65.3 &#177; 11.1 years) undergoing PCIs in this study falls within the confidence limits reported by other studies (58 &#177; 11 years to 71 &#177; 10 years; <xref ref-type="table" rid="table">Table </xref>5). The percentages of comorbidities, such as hypertension, DM, and smoking, reported in this study are also comparable to those in previous studies [<xref ref-type="bibr" rid="scirp.132278-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.132278-ref19">19</xref>] - [<xref ref-type="bibr" rid="scirp.132278-ref38">38</xref>] . Additionally, the percentages of patients presenting with CSA, UA, and ACS are similar to those of previous findings [<xref ref-type="bibr" rid="scirp.132278-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.132278-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.132278-ref41">41</xref>] .</p><p>The longer length of the lesion is a well-established causative factor for stent failure [<xref ref-type="bibr" rid="scirp.132278-ref42">42</xref>] . The literature gives a range of mean MB lesion lengths (8.4 - 42.2 mm). In this study, 43.7% of the lesions were more than 20 mm in length. The use of the American College of Cardiology and the American Heart Association lesion classification system indicated that most of the lesions included in this study were type B (68.8%); the rest were type C. The characteristics of each lesion type is based on the extent of proximal tortuosity, angulation within the narrowed segment, the length of the lesion, and the occurrence of total occlusion, bifurcation lesions, thrombus, or fragile vein graft lesions [<xref ref-type="bibr" rid="scirp.132278-ref44">44</xref>] . The success rates associated with operating on type B and C lesions are moderate (60% - 85%; moderate risk) and low (&lt;60%; high risk), respectively [<xref ref-type="bibr" rid="scirp.132278-ref44">44</xref>] . In the present study, the success rate was reported to be 92.18% which is higher than the specified success range reported by Klein (2008) [<xref ref-type="bibr" rid="scirp.132278-ref44">44</xref>] . The percentage occurrences of LAD (50%), LCX (34.4%), LMCA-LAD (3.1%), and D1 (43.8%) that were observed in this study are in concordance with the meta-analyses reported by Fujisaki (2022) and Kan (2022) [<xref ref-type="bibr" rid="scirp.132278-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.132278-ref41">41</xref>] .</p><p>The results of BCS are significantly influenced by procedures such as FKBI and POT [<xref ref-type="bibr" rid="scirp.132278-ref5">5</xref>] . POT was performed in 80% of the patients in this study as per the 2019 EBC recommendation of using POT consistently for all CBLs [<xref ref-type="bibr" rid="scirp.132278-ref45">45</xref>] . POT is highly recommended regardless of the 2SS techniques chosen as it can repair distortion and improve the apposition of the main vessel stent following FKBI, thereby leading to enhanced procedural success as observed in the present study [<xref ref-type="bibr" rid="scirp.132278-ref12">12</xref>] . Likewise, kissing ballon inflation plays role in optimizing stent apposition, correcting the stent distortion or deformation, and improving access to the side branch [<xref ref-type="bibr" rid="scirp.132278-ref46">46</xref>] . The use of FKBI in 85.9% of the patients is similar to those reported in previous studies, which report that FKBI is used in 64% - 100% of 2SS procedures [<xref ref-type="bibr" rid="scirp.132278-ref40">40</xref>] [<xref ref-type="bibr" rid="scirp.132278-ref41">41</xref>] . The achievement of post procedure TIMI grade 3 flow in all patients suggests the absence of any ischemic myocardial areas. A similar finding was reported by Yurtdas et al. [<xref ref-type="bibr" rid="scirp.132278-ref4">4</xref>] .</p><p>The literature in this field clearly shows procedural success rates for CBLs as 91% - 100%, and this study reinforces this evidence by reporting a success rate of 92.18% [<xref ref-type="bibr" rid="scirp.132278-ref41">41</xref>] [<xref ref-type="bibr" rid="scirp.132278-ref42">42</xref>] . A review by Jyotsana et al. providing evidence from 12 studies on MACE in patients operated with 2SS versus one-stent strategy reported that the incidence of MACE varied from 3.4% to 23% [<xref ref-type="bibr" rid="scirp.132278-ref47">47</xref>] . The present study reported MACE in only 7.8% of the cases which is similar to the MACE occurrences reported in literature The use of IVUS offers tomographic images depicting the structure of the coronary arteries and serves as a valuable tool for assessing lesion geometry, the condition of the reference vessel, and optimizing stent placement [<xref ref-type="bibr" rid="scirp.132278-ref48">48</xref>] . Although the use of IVUS can considerably reduce the occurrence of adverse events during and after PCIs, it should be noted that its use in the present study was reported in only 9.4% of the patients [<xref ref-type="bibr" rid="scirp.132278-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.132278-ref42">42</xref>] [<xref ref-type="bibr" rid="scirp.132278-ref43">43</xref>] .</p></sec><sec id="s5"><title>5. Limitations</title><p>This study has the inherent limitations of a retrospective study design. The small sample size has limited the use of statistical analysis, and many comparisons between different stenting techniques and types of stents used could not be performed. In addition, lesion length in the SB was not used as a marker of the severity of the lesion in this study. Furthermore, the PCI procedure was left to the operator’s discretion. IVUS was not used routinely, and only individuals with symptoms underwent angiograms at follow-up; all these factors may have influenced the outcomes of the analyses in this study.</p></sec><sec id="s6"><title>6. Conclusion</title><p>The application of 2SS is a relatively safe and feasible procedure with a superior procedural success rate for the treatment of complex CBLs. The treatment of these lesions requires meticulous planning and anticipation of the potential challenges. Interventional cardiologists should consider a combination of clinical and procedural criteria along with lesion complexity to predict and improve outcomes with 2SS. They should be updated with the latest practice guidelines and the use of newer-generation stents, adjunctive treatments, and the latest imaging technologies for favorable outcomes. Further studies with larger sample sizes are required to validate the findings of this study.</p></sec><sec id="s7"><title>7. Clinical Implications</title><p>This retrospective study provides the first evidence of how 2SS improves procedural success for treating complex CBLs in an Indian setting. Coronary bifurcation PCI may be operated safely using an upfront two-stent approach.</p></sec><sec id="s8"><title>Acknowledgements</title><p>We would like to thank BioQuest Solutions Pvt. Ltd. for providing editorial assistance.</p></sec><sec id="s9"><title>Authors’ Contributions</title><p>All authors made significant and equal contributions to this study. They collaborated on study design, collected and analyzed the data, interpreted the results, and drafted the manuscript. All authors reviewed and approved the final version of the manuscript.</p></sec><sec id="s10"><title>Funding</title><p>The author would like to acknowledge that this research project did not receive any external funding or financial support.</p></sec><sec id="s11"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s12"><title>Cite this paper</title><p>Kumar, D., Malviya, A., Mishra, A., Chakraborty, R., Mukherjee, S.S., Patra, S., Pande, A., Roy, R.R., Mondal, D., Halder, A. and Shanker, S. (2024) Two-Stent Strategy for Bifurcation Lesions in Percutaneous Transluminal Coronary Angioplasty: Real-World Evidence. World Journal of Cardiovascular Diseases, 14, 140-156. https://doi.org/10.4236/wjcd.2024.143012</p></sec><sec id="s13"><title>Supplementary</title><table-wrap id="table6" ><label><xref ref-type="table" rid="table">Table </xref>S1</label><caption><title> Details of stents used in the study</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Stent type</th><th align="center" valign="middle" >N</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >Biotronik AG</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Cruz</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >14.1</td></tr><tr><td align="center" valign="middle" >Endeavor Sprint</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Endeavor Sprint/Promus</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Endeavor Resolute</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Evermine/Biomime Branch</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >4.7</td></tr><tr><td align="center" valign="middle" >Integrity</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Integrity/Yukon Choice PC</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Orsiro/Yukon Choice Flex</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Promus/Ultimaster</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Promus Premier</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Promus Premier/Integrity</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Promus/Yukon</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Resolute Integrity/Xience Xpedition</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Resolute Onyx</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3.1</td></tr><tr><td align="center" valign="middle" >Supraflex Cruz</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >4.7</td></tr><tr><td align="center" valign="middle" >Supraflex Cruz/Tetrilimus</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Tetriflex/Biomime Branch</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Tetriflex/Siromolint</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Tetrilimus</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >18.8</td></tr><tr><td align="center" valign="middle" >Tetrilimus/Promus</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Tetrilimus/Promus Elite</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Tetrilimus/Ultimaster</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Ultimaster</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >4.7</td></tr><tr><td align="center" valign="middle" >Xience Alpine/Promus</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >YCPC/Ultimaster</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Yukon Choice PC</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >14.1</td></tr><tr><td align="center" valign="middle" >Yukon Choice PC/Xience Pro</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Yukon Choice PC/Integrity</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Yukon Choice PC/Synergy</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6</td></tr></tbody></table></table-wrap></sec></body><back><ref-list><title>References</title><ref id="scirp.132278-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, J.J., Gao, X.F., Han, Y.L., Kan, J., Tao, L., Ge, Z., Tresukosol, D., et al. (2018) Treatment Effects of Systematic Two-Stent and Provisional Stenting Techniques in Patients with Complex Coronary Bifurcation Lesions: Rationale and Design of a Prospective, Randomised and Multicentre DEFINITION II Trial. BMJ Open, 8, e020019.  
https://doi.org/10.1136/bmjopen-2017-020019corr1</mixed-citation></ref><ref id="scirp.132278-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Feldman, D., Beerkens, F., Nicolas, J., Satish, M., Jones, D., Johnson, J.W., et al. (2022) Defining Key Features of Complex Coronary Lesions: An Evidence Based Review of Clinical Practice. Part I: Bifurcations, Left Main Disease, and Calcifications. Reviews in Cardiovascular Medicine, 23, Article No. 197.  
https://doi.org/10.31083/j.rcm2306197</mixed-citation></ref><ref id="scirp.132278-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Park, D.Y., An, S., Jolly, N., Attanasio, S., Yadav, N., Rao, S., et al. (2022) Systematic Review and Network Meta-Analysis Comparing Bifurcation Techniques for Percutaneous Coronary Intervention. Journal of the American Heart Association, 11, e025394. https://doi.org/10.1161/JAHA.122.025394</mixed-citation></ref><ref id="scirp.132278-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Yurtdas, M., Asoglu, R., Ozdemir, M., and Asoglu, E. (2020) An Upfront Two-Stent Strategy for True Coronary Bifurcation Lesions with a Large Side Branch in Acute Coronary Syndrome: A Two-Year Follow-Up Study. Medicina, 56, Article 102.  
https://doi.org/10.3390/medicina56030102</mixed-citation></ref><ref id="scirp.132278-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Jabir, A., Malviya, A., Thomas, J., Vijaykumar, S. Mandalay, A., Joseph, J. and Mathew, R. (2021) Rationale, Design, and Implications of Bifurcation Coronary Stenting: Insight from the Indian Bifurcation Stenting (IBIS) Registry. Cureus, 13, e18027.  
https://doi.org/10.7759/cureus.18027</mixed-citation></ref><ref id="scirp.132278-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Sawaya, F.J., Lefèvre, T., Chevalier, B., Garot, P., Hovasse, T., Morice, M.C., et al. (2016) Contemporary Approach to Coronary Bifurca-Tion Lesion Treatment. JACC Cardiovascular Interventions, 9, 1861-1878.  
https://doi.org/10.1016/j.jcin.2016.06.056</mixed-citation></ref><ref id="scirp.132278-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Choo, G H., and Gurupparan, K. (2022) Provisional Stenting: A Contemporary Relook at the Strategy and Lingering Issues. Cardiology Discovery, 2, 191-196.  
https://doi.org/10.1097/CD9.0000000000000064</mixed-citation></ref><ref id="scirp.132278-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Chandrasekhar, J., Martin, K., and Mehran, R. (2016) Role of Coronary Drug-Eluting Stents in Current Clinical Practice. Clinical Pharmacist, 8, 16-23</mixed-citation></ref><ref id="scirp.132278-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Vinayakumar, D., Mohanan, K.S., and Goyal, K.K. (2018) Balloon Embedded Bifurcation Stenting with Single Stent for Side Branch Protection—Preliminary Results from an Indian Population. Indian Heart Journal, 70, S299-S302.  
https://doi.org/10.1016/j.ihj.2018.06.004</mixed-citation></ref><ref id="scirp.132278-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Mohamed, M.O., Mamas, M.A., Nagaraja, V., Alraies, M.C., Lamelas, P., Tzemos, N., et al. (2019) Dedicated Bifurcation Stents for Coronary Bifurcation Lesions: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials. Journal of Invasive Cardiology, 31, E344-E355.</mixed-citation></ref><ref id="scirp.132278-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Lim, Y., Kim, M.C., Ahn, Y., Sim, D.S., Hong, Y.J., Kim, J.H., et al. (2022) Effect of Stenting Strategy on the Outcome in Patients with Non-Left Main Bifurcation Lesions. Journal of Clinical Medicine, 11, Article No. 5658.  
https://doi.org/10.3390/jcm11195658</mixed-citation></ref><ref id="scirp.132278-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, J.J., Ye, F., Xu, K., Kan, J., Tao, L., Santoso, T., et al. (2020) Multicentre, Randomized Comparison of Two-Stent and Provisional Stenting Techniques in Patients with Complex Coronary Bifurcation Lesions: The DEFINITION II Trial. European Heart Journal, 41, 2523-2536. https://doi.org/10.1093/eurheartj/ehaa543</mixed-citation></ref><ref id="scirp.132278-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Steigen, T.K., Maeng, M., Wiseth, R., Erglis, A., Kumsars, I., Narbute, I., et al. (2006) Randomized Study on Simple versus Complex Stenting of Coronary Artery Bifurcation Lesions: The Nordic Bifurcation Study. Circulation, 114, 1955-1961.  
https://doi.org/10.1161/CIRCULATIONAHA.106.664920</mixed-citation></ref><ref id="scirp.132278-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Hildick-Smith, D., de Belder, A.J., Cooter, N., Curzen, N.P., Clayton, T.C., Oldroyd, K.G., et al. (2010) Randomized Trial of Simple versus Complex Drug-Eluting Stenting for Bifurcation Lesions: The British Bifurcation Coronary Study: Old, New, and Evolving Strategies. Circulation, 121, 1235-1243.  
https://doi.org/10.1161/CIRCULATIONAHA.109.888297</mixed-citation></ref><ref id="scirp.132278-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Alasnag, M., Bharadwaj, A. and Al-Shaibi, K. (2019) Commentary on the Nordic-Baltic Bifurcation Study IV (Randomised Comparison of Provisional Side Branch Stenting versus a Two-Stent Strategy for Treatment of True Coronary bifurcation Lesions Involving a Large Side Branch). Open Heart, 6, e001168.  
https://doi.org/10.1136/openhrt-2019-001168</mixed-citation></ref><ref id="scirp.132278-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Lassen, J.F., Albiero, R., Johnson, T.W., Burzotta, F., Lefèvre, T., Iles, T.L., et al. (2022) Treatment of Coronary Bifurcation Lesions, Part II: Implanting Two Stents. The 16th Expert Consensus Document of the European Bifurcation Club. EuroIntervention, 18, 457-470. https://doi.org/10.4244/EIJ-D-22-00166</mixed-citation></ref><ref id="scirp.132278-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Hildick-Smith, D., Behan, M.W., Lassen, J.F., Chieffo, A., Lefevre, T., Stankovic, G., et al. (2016) The EBC TWO Study (European Bifurcation Coronary TWO): A Randomized Comparison of Provisional T-Stenting versus a Systematic 2 Stent Culotte Strategy in Large Caliber True Bifurcations. Circulation: Cardiovascular Interventions, 9, e003643.  
https://doi.org/10.1161/CIRCINTERVENTIONS.115.003643</mixed-citation></ref><ref id="scirp.132278-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Kumsars, I., Holm, N.R., Niemela, M., Erglis, A., Kervinen, K., Christiansen, E.H., et al. (2020) Randomised Comparison of Provisional Side Branch Stenting versus a Two-Stent Strategy for Treatment of True Coronary Bifurcation Lesions Involving a Large Side Branch: The Nordic-Baltic Bifurcation Study IV. Open Heart, 7, e000947.  
https://doi.org/10.1136/openhrt-2018-000947</mixed-citation></ref><ref id="scirp.132278-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Pan, M., de Lezo, J.S., Medina, A., Romero, M., Segura, J., Pavlovic, D., et al. (2004) Rapamycin-Eluting Stents for the Treatment of Bifurcated Coronary Lesions: A Randomized Comparison of a Simple versus Complex Strategy. American Heart Journal, 148, 857-864. https://doi.org/10.1016/j.ahj.2004.05.029</mixed-citation></ref><ref id="scirp.132278-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Colombo, A., Moses, J.W., Morice, M.C., Ludwig, J., Holmes Jr., D.R., Spanos, V., et al. (2004) Randomized Study to Evaluate Sirolimus-Eluting Stents Implanted at Coronary Bifurcation Lesions. Circulation, 109, 1244-1249.  
https://doi.org/10.1161/01.CIR.0000118474.71662.E3</mixed-citation></ref><ref id="scirp.132278-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Chen, S.L., Zhang, J.J., Ye, F., Chen, Y.D., Patel, T., Kawajiri, K., et al. (2008) Study Comparing the Double Kissing (DK) Crush with Classical Crush for the Treatment of Coronary Bifurcation Lesions: The DKCRUSH-1 Bifurcation Study with Drug-Eluting Stents. European Journal of Clinical Investigation, 38, 361-371.  
https://doi.org/10.1111/j.1365-2362.2008.01949.x</mixed-citation></ref><ref id="scirp.132278-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Colombo, A., Bramucci, E., Saccà, S., Violini, R., Lettieri, C., Zanini, R., et al. (2009) Randomized Study of the Crush Technique versus Provisional Side-Branch Stenting in True Coronary Bifurcations: The CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study. Circulation, 119, 71-78. https://doi.org/10.1161/CIRCULATIONAHA.108.808402</mixed-citation></ref><ref id="scirp.132278-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Chen, S.L., Santoso, T., Zhang, J.J., Ye, F., Xu, Y.W., Fu, Q., et al. (2011) A Randomized Clinical Study Comparing Double Kissing Crush with Provisional Stenting for Treatment of Coronary Bifurcation Lesions: Results from the DKCRUSH-II (Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) Trial. Journal of the American College of Cardiology, 57, 914-920. https://doi.org/10.1016/j.jacc.2010.10.023</mixed-citation></ref><ref id="scirp.132278-ref24"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ye</surname><given-names> F.</given-names></name>,<name name-style="western"><surname> S. Chen</surname><given-names> L.</given-names></name>,<name name-style="western"><surname> Zhang</surname><given-names> J.J.</given-names></name>,<name name-style="western"><surname> Zhu Z.-S.</surname><given-names> Kan</given-names></name>,<name name-style="western"><surname> J.</surname><given-names> Tian</given-names></name>,<name name-style="western"><surname> N.-L.</surname><given-names> et al. </given-names></name>,<etal>et al</etal>. (<year>2012</year>)<article-title>Hemodynamic Changes of Fractional Flow Reserve after Double Kissing Crush and Provisional Stenting Technique for True Bifurcation Lesions</article-title><source> Chinese Medical Journal (English)</source><volume> 125</volume>,<fpage> 2658</fpage>-<lpage>2662</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.132278-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Kervinen, K., Niemela, M., Romppanen, H., Erglis, A., Kumsars, I., Maeng, M., et al. (2013) Clinical Outcome after Crush versus Culotte Stenting of Coronary Artery Bifurcation Lesions: The Nordic Stent Technique Study 36-Month Follow-Up Results. JACC: Cardiovascular Interventions, 6, 1160-1165.  
https://doi.org/10.1016/j.jcin.2013.06.009</mixed-citation></ref><ref id="scirp.132278-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Maeng, M., Holm, N.R., Erglis, A., Kumsars, I., Niemela, M., Kervinen, K., et al. (2013) Long-Term Results after Simple versus Complex Stenting of Coronary Artery Bifurcation Lesions: Nordic Bifurcation Study 5-Year Follow-Up Results. Journal of the American College of Cardiology, 62, 30-34.  
https://doi.org/10.1016/j.jacc.2013.04.015</mixed-citation></ref><ref id="scirp.132278-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Ruiz-Salmeron, R.J., Valenzuela, L.F., Perez, I., Fuentes, M., Rodriguez-Leiras, S., Vizcaino, M., et al. (2013) Approach to Coronary Bifurcation Lesions Using the Everolimus-Eluting Stent: Comparison between a Simple Strategy and a Complex Strategy with T-Stenting. Revista Espacola de Cardiología (English Edition), 66, 636-643. https://doi.org/10.1016/j.rec.2013.03.005</mixed-citation></ref><ref id="scirp.132278-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Chen, S.L., Xu, B., Han, Y.L., Sheiban, I., Zhang, J.J., Ye, F., et al. (2015) Clinical Outcome after DK Crush versus Culotte Stenting of Distal Left Main Bifurcation Lesions: The 3-Year Follow-Up Results of the DKCRUSH-III Study. JACC: Cardiovascular Intervention, 8, 1335-1342. https://doi.org/10.1016/j.jcin.2015.05.017</mixed-citation></ref><ref id="scirp.132278-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Ferenc, M., Ayoub, M., Buttner, H.J., Gick, M., Comberg, T., Rothe, J., et al. (2015) Long-Term Outcomes of Routine versus Provisional T-Stenting for de Novo Coronary Bifurcation Lesions: Five-Year Results of the Bifurcations Bad Krozingen I Study. EuroIntervention, 11, 856-859. https://doi.org/10.4244/EIJV11I8A175</mixed-citation></ref><ref id="scirp.132278-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Kim, Y.H., Lee, J.H., Roh, J.H., Ahn, J.M., Yoon, S.H., Park, D.W., et al. (2015) Randomized Comparisons between Different Stenting Approaches for Bifurcation Coronary Lesions with or without Side Branch Stenosis. JACC: Cardiovascular Intervention, 8, 550-560. https://doi.org/10.1016/j.jcin.2015.01.016</mixed-citation></ref><ref id="scirp.132278-ref31"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhang</surname><given-names> L.</given-names></name>,<name name-style="western"><surname> Zhong W.</surname><given-names> Luo</given-names></name>,<name name-style="western"><surname> Y. and Chen</surname><given-names> L. </given-names></name>,<etal>et al</etal>. (<year>2016</year>)<article-title>A Pilot Study on Culottes versus Crossover Single Stenting for True Coronary Bifurcation Lesions</article-title><source> Acta Cardiological Sinica</source><volume> 32</volume>,<fpage> 450</fpage>-<lpage>459</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.132278-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Ferenc, M., Gick, M., Comberg, T., Rothe, J., Valina, C., Toma, A., et al. (2016) Culotte Stenting vs. TAP Stenting for Treatment of de-Novo Coronary Bifurcation Lesions with the Need for Side-Branch Stenting: The Bifurcations Bad Krozingen (BBK) II Angiographic Trial. European Heart Journal, 37, 3399-3405.  
https://doi.org/10.1093/eurheartj/ehw345</mixed-citation></ref><ref id="scirp.132278-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, X.W., Zhao, D.H., Peng, H.Y., Fan, Q., Ma, Q., Xu, Z.Y., et al. (2016) Randomized Comparison of the Crush versus the Culotte Stenting for Coronary Artery Bifurcation Lesions. Chinese Medical Journal (English), 129, 505-510.  
https://doi.org/10.4103/0366-6999.176997</mixed-citation></ref><ref id="scirp.132278-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Chen, S.-L., Santoso, T., Zhang, J.-J., Ye, F., Xu, Y.-W., Fu, Q., et al. (2017) Clinical Outcome of Double Kissing Crush versus Provisional Stenting of Coronary Artery Bifurcation Lesions: The 5-Year Follow-Up Results from a Randomized and Multicenter DKCRUSH-II Study (Randomized Study on Double Kissing Crush Technique versus Provisional Stenting Technique for Coronary Artery Bifurcation Lesions). Circulation: Cardiovascular Interventions, 10, e004497.  
https://doi.org/10.1161/CIRCINTERVENTIONS.116.004497</mixed-citation></ref><ref id="scirp.132278-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X., Li, X., Zhang, J.J., Han, Y., Kan, J., Chen, L., et al. (2019) DKCRUSH-V Investigators. 3-Year Outcomes of the DKCRUSH-V Trial Comparing DK Crush With Provisional Stenting for Left Main Bifurcation Lesions. JACC: Cardiovascular Intervention, 12, 1927-1937. https://doi.org/10.1016/j.jcin.2019.04.056</mixed-citation></ref><ref id="scirp.132278-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, J.-J., Ye, F., Xu, K., Kan, J., Tao, L., Santoso, T., et al. (2020) Multicentre, Randomized Comparison of Two-Stent and Provisional Stenting Techniques in Patients with Complex Coronary Bifurcation Lesions: The DEFINITION II Trial. European Heart Journal, 41, 2523-2536. https://doi.org/10.1093/eurheartj/ehaa543</mixed-citation></ref><ref id="scirp.132278-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Kim, J., Lee, J.M., Park, T.K., Yang, J.H., Hahn, J.Y., Choi, J.H., et al. (2021) Optimal Strategy for Side Branch Treatment in Patients with Left Main Coronary Bifurcation Lesions. Revista Espacola de Cardiología (English Edition), 74, 691-699.  
https://doi.org/10.1016/j.rec.2020.06.011</mixed-citation></ref><ref id="scirp.132278-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Hildick-Smith, D., Egred, M., Banning, A., Brunel, P., Ferenc, M., Hovasse, T., et al. (2021) The European Bifurcation Club Left Main Coronary Stent study: A Randomized Comparison of Stepwise Provisional vs. Systematic Dual Stenting Strategies (EBC MAIN). European Heart Journal, 42, 3829-3839.  
https://doi.org/10.1093/eurheartj/ehab283</mixed-citation></ref><ref id="scirp.132278-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Kan, J., Luo, S., Wang, D., Cai, D., Zhang, X. and Kan, J. (2022) Impact of Side Branch Lesion Length on Clinical Outcome after Coronary Stenting Techniques in Patients with Coronary Artery Bifurcation Disease: A Meta-Analysis. Cardiology Discovery, 2, Article 157173. https://doi.org/10.1097/CD9.0000000000000066</mixed-citation></ref><ref id="scirp.132278-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Ford, T.J., McCartney, P., Corcoran, D., Collison, D., Hennigan, B., McEntegart, M., et al. (2018) Single- versus 2-Stent Strategies for Coronary Bifurcation Lesions: A Systematic Review and Meta-Analysis of Randomized Trials with Long-Term Follow-Up. Journal of the American Heart Association, 7, e008730.  
https://doi.org/10.1161/JAHA.118.008730</mixed-citation></ref><ref id="scirp.132278-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Fujisaki, T., Kuno, T., Numasawa, Y., Takagi, H., Briasoulis, A., Kwan, T., et al. (2022) Provisional or 2-Stent Technique for Bifurcation Lesions in the Second-Generation Drug-Eluting Stent Era. Journal of the Society for Cardiovascular Angiography and Interventions, 1, Article 100410. https://doi.org/10.1016/j.jscai.2022.100410</mixed-citation></ref><ref id="scirp.132278-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Wang, S., Liang, C., Wang, Y., Sun, S., Wang, Y., Suo, M., et al. (2022) The Long-Term Clinical Outcomes of Intravascular Ultrasound-Guided versus Angiography-Guided Coronary Drug Eluting Stent Implantation in long de novo Coronary Lesions: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 9, 944143. https://doi.org/10.3389/fcvm.2022.944143</mixed-citation></ref><ref id="scirp.132278-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Di Gioia, G., Sonck, J., Ferenc, M., Chen, S.L., Colaiori, I., Gallinoro, E., et al. (2020) Clinical Outcomes Following Coronary Bifurcation PCI Techniques: A Systematic Review and Network Meta-Analysis Comprising 5,711 Patients. JACC: Cardiovascular Interventions, 13, 1432-1444. https://doi.org/10.1016/j.jcin.2020.03.054</mixed-citation></ref><ref id="scirp.132278-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Klein, L.W. and Krone, R.J. (2008) Angiographic Characterization of Lesion Morphology. Cardiac Interventions Today, 8, 44-49.</mixed-citation></ref><ref id="scirp.132278-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Banning, A.P., Lassen, J.F., Burzotta, F., Lefèvre, T., Darremont, O., Hildick-Smith, D., et al. (2019) Percutaneous Coronary Intervention for Obstructive Bifurcation Lesions: The 14th Consensus Document from the European Bifurcation Club. EuroIntervention, 15, 90-98. https://doi.org/10.4244/EIJ-D-19-00144</mixed-citation></ref><ref id="scirp.132278-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Sgueglia, G.A. and Chevalier, B. (2012) Kissing Balloon Inflation in Percutaneous Coronary Interventions. JACC: Cardiovascular Interventions, 5, 803-811.  
https://doi.org/10.1016/j.jcin.2012.06.005</mixed-citation></ref><ref id="scirp.132278-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Jyotsna, M. (2020) Coronary Bifurcation Lesion-Management. Indian Journal of Cardiovascular Disease in Women—WINCARS, 5, 137-154.  
https://doi.org/10.1055/s-0040-1713963</mixed-citation></ref><ref id="scirp.132278-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Lee, S.Y., Choi, K.H., Song, Y.B. and Park, T.K. (2022) Use of Intravascular Ultrasound and Long-Term Cardiac Death or Myocardial Infarction in Patients Receiving Current Generation Drug-Eluting Stents. Scientific Reports, 12, Article No. 8237.  
https://doi.org/10.1038/s41598-022-04807-w</mixed-citation></ref></ref-list></back></article>